Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

28.54
+0.16000.56%
Pre-market: 28.540.00000.00%07:02 EDT
Volume:5.41M
Turnover:154.84M
Market Cap:3.60B
PE:-6.11
High:29.06
Open:28.39
Low:28.12
Close:28.38
52wk High:43.15
52wk Low:25.77
Shares:126.00M
Float Shares:123.00M
Volume Ratio:0.81
T/O Rate:4.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:8.81
PE(LYR):-8.94

Loading ...

Truist Financial Sticks to Their Buy Rating for Viking Therapeutics (VKTX)

TIPRANKS
·
Jul 30

Madrigal Pharmaceuticals Q2 Revenue Rises 71% on Rezdiffra Demand

Reuters
·
Jul 30

Viking Therapeutics Inc Files for Mixed Shelf; Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Jul 30

Viking Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Viking Therapeutics Reports Q2 Milder-than-expected Net Loss as Obesity Trials Advance

Reuters
·
Jul 30

Viking Therapeutics reports Q2 EPS ($1.10) vs. (58c) last year

TIPRANKS
·
Jul 30

Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate

Benzinga Earnings
·
Jul 30

Viking Therapeutics Q2 EPS USD -1.1 Vs. IBES Estimate USD -1.25

Reuters
·
Jul 30

Viking Therapeutics (VKTX) Stock Looks Above Fair Value Today

Simply Wall St.
·
Jul 30

Viking Therapeutics options imply 8.1% move in share price post-earnings

TIPRANKS
·
Jul 30

Viking Therapeutics Inc Expected to Post a Loss of $1.25 a Share - Earnings Preview

Reuters
·
Jul 28

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Summit Therapeutics (SMMT) and Progyny (PGNY)

TIPRANKS
·
Jul 24

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

THOMSON REUTERS
·
Jul 23

Viking Therapeutics to Report Q2 Results After Market Close, Host Conference Call

Reuters
·
Jul 23

Viking Therapeutics (VKTX) Could Be 61% Undervalued As It Starts VK3019 Trial

Simply Wall St.
·
Jul 18

VKTX: Buy Rating Backed by VK2735’s Potential to Transform Obesity Maintenance Therapy Ahead of Key Phase I Data

TIPRANKS
·
Jul 17

Viking Therapeutics Posts Corporate Presentation Highlighting Vk2735 Obesity Drug Program Pipeline

Reuters
·
Jul 15

Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy?

Simply Wall St.
·
Jul 10

Movement Alert|Viking Therapeutics Rises 8.68% in Regular Trading, Phase 1 Clinical Trial of Novel Weight Loss Drug VK3019 Boosts Market Sentiment

Market Focus
·
Jul 08

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Reuters
·
Jul 08